Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics crawled date : 2022 - 10 - 26 save search
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
Published: 2022-10-26 (Crawled : 22:00) - biospace.com/
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
ARCT 4 | $30.15 2.87% 2.79% 390K
|
Health Technology
|
| O: -0.12%
H: 8.05%
C: 2.28%
report therapeutics financial update results
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-10-26 (Crawled : 22:00) - biospace.com/
VKTX | $67.94 1.48% 1.46% 2.1M
|
Health Technology
|
| O: -2.2%
H: 12.5%
C: 3.75%
LGND | $80.01 0.3% 0.3% 160K
|
Health Technology
|
| O: 0.48%
H: 2.13%
C: -0.81%
therapeutics financial update results
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
Published: 2022-10-26 (Crawled : 21:00) - globenewswire.com
FDMT | $26.76 1.94% 1.91% 480K
|
Health Technology
|
| O: 1.17%
H: 34.79%
C: 14.63%
fibrosis lung disease trial therapeutics molecular cystic fibrosis
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
Published: 2022-10-26 (Crawled : 21:00) - biospace.com/
DMAC | $2.39 -0.41% 16K
|
Health Technology
|
| O: 0.7%
H: 2.8%
C: -0.69%
trial therapeutics update
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
Published: 2022-10-26 (Crawled : 21:00) - globenewswire.com
TVTX | $6.165 -2.45% -2.51% 750K
|
Health Technology
|
| O: 2.16%
H: 1.1%
C: -1.06%
kidney week therapeutics
Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium
Published: 2022-10-26 (Crawled : 19:00) - globenewswire.com
RAIN | $1.21 0.0% 3.7M
|
Manufacturing
|
| O: 5.5%
H: 5.04%
C: -2.52%
symposium therapeutics presentation
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Published: 2022-10-26 (Crawled : 14:00) - globenewswire.com
GTHX | $4.08 -5.34% -5.64% 570K
|
Health Technology
|
| O: -0.62%
H: 5.64%
C: -0.81%
lung trilaciclib therapeutics cancer study initiated
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
Published: 2022-10-26 (Crawled : 13:20) - biospace.com/
ALDX 4 | $3.87 -6.97% -7.49% 720K
|
Health Technology
|
| O: 0.0%
H: 8.0%
C: 7.81%
meeting therapeutics presentation
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
RLFTF | $1.32 11.45% 1K
|
n/a
|
| O: -13.46%
H: 28.44%
C: 20.0%
therapeutics
Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -0.81%
H: 5.57%
C: 3.28%
treatment patent application celiprolol therapeutics
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
UTHR | $231.715 -1.43% -1.45% 500K
|
Health Technology
|
| O: 0.6%
H: 1.62%
C: -0.18%
report therapeutics corporation financial results market
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
CADL | $5.89 1.2% 1.19% 1.1M
|
|
| O: 7.69%
H: 0.0%
C: -9.52%
immunotherapy car-t therapeutics therapy study
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
BDTX A | $5.34 2.3% 2.25% 290K
|
Health Technology
|
| O: 0.6%
H: 11.98%
C: 4.19%
bdtx-1535 preclinical symposium therapeutics molecular cancer
Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
SRPT | $117.27 -0.88% -0.89% 590K
|
Health Technology
|
| O: 0.3%
H: 3.31%
C: 1.66%
therapeutics financial results
Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -0.81%
H: 5.57%
C: 3.28%
patent application therapeutics
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
AGRX | $0.3704 0.0% 35K
|
Health Technology
|
| O: -0.48%
H: 6.07%
C: 0.6%
report therapeutics financial update results
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
ALLO | $3.5 -1.41% -1.43% 1.4M
|
Health Technology
|
| O: -0.31%
H: 9.94%
C: 7.07%
report therapeutics financial results
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
EFTR | $2.0 3.63% 3.5% 230K
|
|
| O: -0.33%
H: 6.4%
C: 4.7%
covid-19 treatment trial therapeutics phase 2b
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
|
| O: 2.22%
H: 8.7%
C: 8.7%
MCRB | $0.6361 2.95% 2.86% 4.2M
|
Health Technology
|
| O: 1.39%
H: 16.24%
C: 12.65%
ser-109 fda application license therapeutics review infection
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference
Published: 2022-10-26 (Crawled : 12:00) - nutriband.com
NTRB | $4.02 2.81% 2.74% 20K
|
Manufacturing
|
| O: 0.24%
H: 10.71%
C: -0.95%
SRNE | $0.033 -8.85% 2M
|
Health Technology
|
| O: 5.63%
H: 0.0%
C: 0.0%
conference therapeutics study phase 2b
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
BSGM | $1.52 38.18% 3.2M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
VERO | $0.829 35.9% 26.42% 120K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.